Quanterix Corp (QTRX) FinancialsQTRXQuanterix Corp

Quanterix Corporation (QTRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 71.3% of total sales, equivalent to $23.48M. Other significant revenue streams include Service and other revenue and Collaboration and license revenue. Understanding this composition is critical for investors evaluating how QTRX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Quanterix Corporation maintains a gross margin of 38.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -68.37%, while the net margin is -148.71%. These profitability ratios, combined with a Return on Equity (ROE) of -46.48%, provide a clear picture of how effectively QTRX converts its operational activities into shareholder value.

In the context of the broader market, QTRX competes directly with industry leaders such as VANI and APYX. With a market capitalization of $141.41M, it holds a leading position in the sector. When comparing efficiency, QTRX's gross margin of 38.52% stands against VANI's N/A and APYX's 63.89%. Such benchmarking helps identify whether Quanterix Corporation is trading at a premium or discount relative to its financial performance.

Quanterix reported a Q2 2026 revenue of $32.9 million, a 34% year-over-year growth, but a 23% decline when adjusted for pre-acquisition results from Akoya. The gross margin has decreased to 38.52% in Q2 2026, down from previous quarters, indicating declining profitability.